Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients (PROTEOHSEPS)
The mortality induced by infections in onco-hematological patients is abnormally high at the acute phase of septic shock. Consequently, it is important to detect the population with a high risk of short term mortality among patients with a septic shock. The aim of this study is the evaluation of predictive proteic profile on the short term mortality in the acute phase of septic shock in cancer patients.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients|
- Identification and characterization of early proteic biomarkers predictive of short term mortality in cancer patients with septic shock. [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- Research of clinical and biological prognostic factors. [ Time Frame: 1 month ] [ Designated as safety issue: No ]
|Study Start Date:||August 2008|
|Study Completion Date:||May 2011|
|Primary Completion Date:||April 2011 (Final data collection date for primary outcome measure)|
Experimental: SELDI-TOF MS
The proteic profiling is performed by SELDI-TOF mass spectroscopy.
Other: SELDI-TOF MS for plasmatic proteic profile
An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
Method: Monocentric prospective study with diagnostic and prognostic expectations.
Identification and characterization of early proteic biomarkers predictive of short term mortality in cancer patients with septic shock.
Research of clinical and biological prognostic factors.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00930085
|Principal Investigator:||Djamel MOKART, MD||Institut Paoli-Calmettes|